Paper Details

  1. Home
  2. Paper Details

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

Author: , BlindauerKaren, FahnStanley, KieburtzKarl, SchwidSteven R, ShoulsonIra, SternMatthew, WhiteWilliam B, deMarcaidaJ Antonelle

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rasagiline, a selective MAO-B inhibitor for Parkinson's disease, did not cause clinically significant tyramine reactions in patients receiving 0.5 to 2 mg daily. Therefore, rasagiline can be used as monotherapy or adjunct to levodopa without dietary tyramine restrictions.
Paper Details　
Original Abstract of the Article :
Rasagiline is a novel, potent, and selective MAO-B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50-75 mg) were perf...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/mds.21048

データ提供：米国国立医学図書館（NLM）

Safely Managing Parkinson's Disease

[Parkinson's disease] is a chronic neurological disorder that affects millions of people worldwide. This study focused on [rasagiline], a [selective MAO-B inhibitor], and its [interaction with tyramine], a compound found in certain foods. The researchers conducted [tyramine challenges] in [72 rasagiline-treated and 38 placebo-treated Parkinson's disease (PD) patients] to assess the drug's [safety] in relation to dietary tyramine.

Rasagiline: A Safe and Effective Treatment

The study found that [rasagiline] did not result in [clinically significant tyramine reactions] in [most patients] even when they consumed [tyramine]. This finding provides reassurance that [rasagiline] can be used [safely] as [monotherapy or adjunct to levodopa] in [Parkinson's disease patients] without the need for [specific dietary tyramine restrictions].

A Journey Towards Better Health

Imagine a camel traversing a desert, navigating its way through diverse terrains and unpredictable conditions. This study illustrates the complexity of managing [Parkinson's disease] and highlights the importance of [individualized treatment plans] that take into account factors like [diet and medication interactions].

Dr. Camel's Conclusion

This research provides valuable information about the safety and effectiveness of rasagiline in managing Parkinson's disease. The findings offer patients and their healthcare providers greater confidence in using rasagiline as a safe and effective treatment option.

Date :
  1. Date Completed 2007-02-02
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

16856145

DOI: Digital Object Identifier

10.1002/mds.21048

Related Literature

Article Analysis
・Effects of rasagiline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.